Cardiff Oncology, Inc. Logo

Cardiff Oncology, Inc.

A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.

CRDF | US

Overview

Corporate Details

ISIN(s):
US14147L1089
LEI:
Country:
United States of America
Address:
11055 FLINTKOTE AVENUE, 92121 SAN DIEGO

Description

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-06 17:08
8-K
English ZIP 114.3 KB
2025-11-06 17:00
10-Q
English ZIP 1.0 MB
2025-08-28 18:56
S-8
English ZIP 460.8 KB
2025-08-14 19:06 English ZIP 10.1 KB
2025-07-31 18:05
4
English ZIP 6.7 KB
2025-07-29 18:10
8-K
English ZIP 29.4 MB
2025-07-29 18:00
10-Q
English ZIP 1010.8 KB
2025-07-29 13:26 English ZIP 8.3 KB
2025-07-08 18:05
3
English ZIP 6.0 KB
2025-06-30 11:39 English ZIP 6.9 KB
2025-06-30 11:38 English ZIP 7.0 KB
2025-06-30 11:38 English ZIP 6.9 KB
2025-06-27 22:45 English ZIP 5.2 KB
2025-06-27 21:40 English ZIP 4.2 KB
2025-06-27 21:38 English ZIP 6.9 KB

Automate Your Workflow. Get a real-time feed of all Cardiff Oncology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cardiff Oncology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cardiff Oncology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BioSenic SA Logo
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
Belgium
BIOS
BIOTECH Logo
A biotechnology group offering preclinical services, intein development, and licensing.
Spain
BST
Biovica International B Logo
Develops blood-based biomarker assays for cancer therapy monitoring.
Sweden
BIOVIC
Bonus BioGroup Ltd. Logo
A clinical-stage biotech firm developing cell therapy and tissue engineering products.
Israel
BONS
BRAIN Biotech AG Logo
Develops enzymes and microorganisms for the food, chemical, and life sciences sectors.
Germany
BNN
BriaCell Therapeutics Corp. Logo
Clinical-stage immuno-oncology company developing cellular immunotherapies for cancer.
United States of America
BCTX
BSF ENTERPRISE PLC Logo
Develops cell-based solutions for cultivated meat, leather, and corneal repair.
United Kingdom
BSFA
BullFrog AI Holdings, Inc. Logo
A technology company applying AI and machine learning to drug development.
United States of America
BFRG
Burning Rock Biotech Ltd Logo
A global diagnostics company specializing in precision oncology using NGS technology.
United States of America
BNR
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for B cell-mediated autoimmune diseases.
United States of America
CABA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.